Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers (GAB-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03817346
Recruitment Status : Recruiting
First Posted : January 25, 2019
Last Update Posted : January 25, 2019
Sponsor:
Collaborator:
Smerud Medical Research International AS
Information provided by (Responsible Party):
Gabather AB

Brief Summary:

This study does not target any disease or condition in itself, but is evaluating the safety, tolerability and pharmacokinetics of single oral doses of GT-002 in the setting of healthy volunteers.

A longer-term objective is to apply the findings from this study to design and later conduct a clinical development programme of GT-002 as a medication to treat schizophrenia.


Condition or disease Intervention/treatment Phase
Safety and Tolerability Drug: GT-002 Drug: Placebo oral capsule Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Single ascending dose
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Double blinde
Primary Purpose: Basic Science
Official Title: A Phase I, Randomised, Double-blind, Placebo-controlled Study in Healthy Male Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of Ascending Single Oral Doses of GT-002
Actual Study Start Date : December 17, 2018
Estimated Primary Completion Date : March 31, 2019
Estimated Study Completion Date : March 31, 2019

Arm Intervention/treatment
Active Comparator: Experimental GT-002 SAD
Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Six of out 8 subjects per cohort will be randomized to receive GT-002.
Drug: GT-002
Single ascending dose

Placebo Comparator: Experimental Placebo oral capsule SAD
Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Two of out 8 subjects per cohort will be randomized to receive GT-002.
Drug: Placebo oral capsule
Comparator single ascending dose




Primary Outcome Measures :
  1. Adverse Events (AEs) [ Time Frame: Day 1 to day 3 ]
    To evaluate the safety and tolerability GT-002 in healthy subjects by assessing the number, severity and type of adverse events, including changes in vital signs, physical examinations, laboratory safety tests and ECGs


Secondary Outcome Measures :
  1. Pharmacokinetic parameter AUCt [ Time Frame: Day1 to day 3 ]
    Area under the curve from the time of dosing until the last quantifiable concentration

  2. Pharmacokinetic parameter AUC0-24 [ Time Frame: Day1 to day 2 ]
    Area under the curve from the time of dosing until 24 hours post dosing

  3. Pharmacokinetic parameter AUC0-infinity [ Time Frame: day 1 to day 3 ]
    Area under the curve from the time of dosing extrapolated to infinity

  4. Pharmacokinetic parameter Cmax [ Time Frame: Day 1 to day 3 ]
    Maximum concentration (Cmax)

  5. tmax [ Time Frame: Day 1 to day 3 ]
    Time to maximum concentration

  6. t1/2 [ Time Frame: Day 1 to day 3 ]
    Apparent terminal elimination half-life



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject is willing and able to give written informed consent for participation in the study. Sufficient command of the Finnish language will be needed for informed consent and adequate communication with the study personnel.
  2. Healthy male subjects from 18 up to 45 years of age.
  3. Body mass index (BMI) from 18 kg/m2 up to 28 kg/m2.
  4. Body weight from 60 kg up to 120 kg.
  5. Clinically normal medical history, physical findings, vital signs, ECG and laboratory values as judged by the investigator at the time of the screening visit. A subject with a clinical abnormality or laboratory parameters outside of the reference range for the population being studied may be included at the investigator´s discretion provided the finding is unlikely to introduce additional risk factors, jeopardize study integrity, or to interfere with the study assessments or procedures.
  6. Subjects must be willing to use condom or other contraceptive methods with a failure rate of < 1% and refrain from donating sperm from the date of dosing until one month after last dosing.

    -

Exclusion Criteria:

  1. Current or history of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
  2. History of any type of cancer.
  3. Subjects considered unlikely to comply with study procedures, restrictions and requirements
  4. Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the administration of investigational product that is likely to introduce additional risk factors, jeopardize study integrity, or to interfere with the study assessments or procedures
  5. Any clinically significant abnormalities in clinical chemistry, haematology, coagulation or urinalysis results at the time of screening visit as judged by the investigator
  6. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody or human immunodeficiency virus (HIV)
  7. After 10 minutes of supine rest, abnormal vital signs defined as any of the following:

    1. Systolic blood pressure > 140 mm Hg (average of two measurements)
    2. Diastolic blood pressure > 90 mm Hg (average of two measurements)
    3. Heart rate < 40 or > 85 beats per minute (average of two measurements)
    4. Body temperature (auricular) ≥38oC
  8. Prolonged QTcF interval (>450 ms), clinically significant cardiac arrhythmia or any other clinically significant abnormalities in the resting ECG as judged by the investigator
  9. Intake of any medication, vitamin or mineral supplement product that could affect the outcome of the study, within 2 weeks prior to the first study treatment administration or less than 5 times the half-life of the medication. Possible prior use of enzyme inducing drugs will be considered case-by-case by the investigator.
  10. Any blood donation/blood loss > 250 ml during the 3 months prior to screening
  11. Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical trial that included drug treatment within 3 months of the administration of investigational product in this study. Subjects consented and screened but not dosed in previous phase I studies can be included in this study.
  12. Current or history of alcohol or drug abuse within the last 5 years, current excessive use of alcohol (current regular alcohol drinking of more than 24 units/week) or use of illicit drugs.
  13. Positive screen for drugs of abuse at screening or on admission to the unit or positive breath test result for alcohol at screening or on admission to the unit prior to the administration of investigational product.
  14. Known allergy to the components used in the formulation of GT-002.
  15. Current smokers or users of nicotine products. Irregular use of nicotine (e.g. smoking, snuffing, and chewing tobacco) up to five doses per week is allowed before screening visit.
  16. Intake of >5 cups of coffee/day or the corresponding amount of other caffeine containing beverages (e.g. energy drinks containing caffeine) during the study.
  17. Subjects who have planned any scheduled invasive treatment or medical/surgical procedure during the study period.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03817346


Contacts
Layout table for location contacts
Contact: Stefan Rehnmark, PhD +46 73-647 88 42 sr@gabather.com
Contact: Johanna Pasquariello +46 70-725 79 95 jp@gabather.com

Locations
Layout table for location information
Finland
CRST Oy, Clinical Research Services Turku Recruiting
Turku, Finland, 20520
Contact: Riitta Filppu    +358 2 420 64 706    riitta.filppu@crst.fi   
Contact: Reijo Kunelius    +358 400 601153    reijo.kunelius@crst.fi   
Sponsors and Collaborators
Gabather AB
Smerud Medical Research International AS
Investigators
Layout table for investigator information
Study Chair: Yvonne Peltonen Smerud Medical Research Finland Ab/Oy

Layout table for additonal information
Responsible Party: Gabather AB
ClinicalTrials.gov Identifier: NCT03817346     History of Changes
Other Study ID Numbers: GAB-001
First Posted: January 25, 2019    Key Record Dates
Last Update Posted: January 25, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gabather AB:
Safety
Tolerability
Pharmacokinetics